Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection
Abstract
Copyright
© 2004, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and Ribavirin
Jancoriene L, Norvydaite D, Galgauskas S, Balciunaite E. Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and Ribavirin. Hepat Mon. 2014;14(2):e15124. doi: https://doi.org/10.5812/hepatmon.15124
Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:
Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea
Kim H, Kim I, Jeon B, Lee S, Kim S, et al. Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea. Hepat Mon. 2012;12(7):. doi: https://doi.org/10.5812/hepatmon.6170
Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
Turker K, Tas B, Ozkaya M, Tas E, Caglar A, et al. Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy. Hepat Mon. 2015;15(3):e24804. doi: https://doi.org/10.5812/hepatmon.24804
The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial
Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:
- Scopus by DOI: 0
Last Update: 2 weeks ago
- Scopus by Title: 0
Last Update: 2 weeks ago
- Scopus by Title (Ref): 0
Last Update: 2 weeks ago
- CrossRef: 0
Last Update: 4 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC